Higher-than-usual doses of radiation within the remedy of inoperable lung cancer could be safely mixed with immunotherapy with out growing the danger of extreme lung irritation (pneumonitis). This is the important thing discovering of a current study performed by Karl Landsteiner University of Health Sciences (KL Krems).
The paper is published within the journal Strahlentherapie und Onkologie.
Patients who acquired 70 Gy of radiation—a dose above the traditional protocol—previous to remedy with the immune checkpoint inhibitor durvalumab didn’t develop pneumonitis extra often than these given a decrease dose. At the identical time, preliminary knowledge counsel a big survival profit. The findings, based mostly on a retrospective analysis of practically 40 sufferers, counsel that extra intensive radiotherapy could provide improved outcomes with out compromising security in chosen instances.
Lung cancer stays one of the crucial frequent and deadliest types of cancer worldwide. For sufferers with inoperable stage III non-small cell lung cancer (NSCLC), the established normal of care is concurrent chemoradiotherapy (CCRT) adopted by immunotherapy with durvalumab—significantly for tumors that categorical the PD-L1 protein, which permits cancer cells to evade the physique’s immune defenses.
However, each radiotherapy and immunotherapy are recognized to hold a threat of inducing pneumonitis. As a consequence, complete radiation doses have historically been restricted to 60 Gy (grey, the unit of absorbed radiation dose). Researchers at KL Krems got down to examine whether or not larger doses—which might doubtlessly result in higher tumor {control}—might be administered with out growing the danger of significant negative effects.
More dose, no further burden
“As a part of a retrospective medical study, we investigated whether or not growing the radiation dose to 70 Gy would result in the next incidence of pneumonitis—and it didn’t,” explains Dr. Felix Schragel, specialist in pulmonology at University Hospital Krems, a educating and analysis middle of KL Krems. “In reality, there was a transparent development towards improved total survival.”
Of the research individuals, 29 acquired the upper dose, whereas 10 had been handled with an individually lowered dose. Both teams had comparable baseline traits, permitting for a dependable and significant comparability. The incidence of pneumonitis was comparable in each teams and in line with knowledge from earlier research. In addition, most instances had been gentle to average in severity.
In complete, 38.5% of individuals developed pneumonitis. However, the speed was truly decrease within the 70 Gy group, at 34.5%, in comparison with 50% within the group that acquired the decrease dose. Only one case of extra extreme pneumonitis (grade 3) was reported—and it occurred within the lower-dose group.
The survival knowledge was significantly hanging: within the high-dose group, greater than 93% of sufferers had been nonetheless alive one 12 months after remedy—and that determine remained nearly unchanged on the four-year mark. By distinction, the median survival within the lower-dose group was 31 months, and tumor development was extra frequent on this group.
Precise planning ensures security
Radiation-induced lung injury was averted because of cautious and exact remedy planning. In each teams, the imply lung dose (MLD) was stored under the essential threshold of 20 Gy.
“As lengthy as clinicians adhere to established security limits—particularly with regard to low-dose lung volumes—we do not count on to see an elevated fee of pneumonitis,” says Dr. Schragel. “These outcomes clearly present that administering the next radiation dose to the tumor doesn’t essentially imply the next threat of inflammatory negative effects—supplied the remedy is nicely deliberate.”
The study highlights the potential for extra customized remedy methods in sufferers with unresectable NSCLC.
“For chosen sufferers with secure lung perform, intensified radiotherapy might considerably enhance total survival,” provides Dr. Schragel. “And I’m significantly happy that KL Krems is taking a number one function on this space—producing analysis with direct relevance to medical practice.”
At the identical time, the findings underline the significance of recurrently re-evaluating established remedy thresholds within the gentle of evolving remedy approaches similar to immunotherapy.
More info:
Felix Schragel et al, High radiation dose in chemoradiotherapy adopted by immunotherapy with durvalumab in sufferers with stage III non-small cell lung cancer doesn’t enhance threat for pneumonitis, Strahlentherapie und Onkologie (2025). DOI: 10.1007/s00066-025-02369-0
Provided by
Karl Landsteiner University of Health Sciences
Citation:
High-dose radiotherapy could be protected and promising for lung cancer together with immunotherapy ( 13)
14
high-dose-radiotherapy-safe-lung.html
.
. The content material is supplied for info functions solely.